ClinicalTrials.gg

Program

endoxifen

Also written as “(Z)-endoxifen”, “Z-Endoxifen” and “Endoxifen”.

Its studies are mostly in Puberty, Precocious · Breast Neoplasms, led by 2 companies.

Furthest: phase 3, since Oct 16, 20205 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Atossa Therapeutics42 open or runningphase 2since Oct 16, 2020Oct 16, 2020Nov 2026phase 2 · NCT05607004
Jina Pharmaceuticals10 open or runningphase 3since Mar 16, 2020Mar 16, 2020none ahead

Also a collaborator on its studies: inclin-inc, novum-pharmaceutical-research-services and lambda-therapeutic-research-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2020First study: phase 3 study in Bipolar I DisorderNew to Jina PharmaceuticalsJina Pharmaceuticals · NCT04315792 · 124 enrolled · United States
  2. Oct 16, 2020Atossa Therapeutics's first study: phase 2 study in Mammographic Breast DensityNew to Atossa TherapeuticsAtossa Therapeutics · NCT04616430 · 90 enrolled · Sweden
  3. Sep 27, 2021Phase 2 study in Breast DensityAtossa Therapeutics · NCT05068388 · 240 enrolled · Sweden
  4. Oct 26, 2022Phase 2 study in Breast NeoplasmsAtossa Therapeutics · NCT05607004 · 87 enrolled · United States
  5. Oct 6, 2026Phase 2 study in Puberty, PrecociousAtossa Therapeutics · NCT07869732 · 6 planned · United States

Ahead

  1. Nov 2026Primary completion: phase 2 study in Breast NeoplasmsAtossa Therapeutics · NCT05607004
  2. Jun 2028Primary completion: phase 2 study in Puberty, PrecociousAtossa Therapeutics · NCT07869732

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07869732Puberty, Precocious · United States2Not yet recruitingAtossa TherapeuticsJun 20286
NCT05607004Breast Neoplasms · United States2Active, not recruitingAtossa TherapeuticsNov 202687
NCT05068388Breast Density · Sweden2CompletedAtossa TherapeuticsJun 14, 2024240
NCT04616430Mammographic Breast Density · Sweden2CompletedAtossa TherapeuticsSep 10, 201890
NCT04315792Bipolar I Disorder · United States3CompletedJina PharmaceuticalsJan 25, 2021124

How it is read

Names in the registry

  • “(Z)-endoxifen”, 2 entries
  • “Z-Endoxifen”, 1 entry
  • “Endoxifen”, 1 entry
  • “Topical endoxifen”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.